Markets:

Overview

News

Currencies

International

Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.040 +0.010 (+0.49%)

Streaming Delayed Price Updated: 12:57 PM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar ↗

February 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 08, 2022

Gainers Second Sight Medical (NASDAQ:EYES) stock increased by 7.8% to $1.51 during Tuesday's pre-market session. The market value of their outstanding shares is at $59...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

February 08, 2022

Good morning! We've got another busy day ahead of us so let's get right into it with the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

Analyst Ratings For Editas Medicine ↗

October 19, 2021

Within the last quarter, Editas Medicine (NASDAQ:EDIT) has observed the fo...

Via Benzinga

21 Stocks Moving in Tuesday's Pre-Market Session ↗

February 08, 2022

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Also check out this: Moderna And 4 Other Stocks Sold By...

Via Benzinga

Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review ↗

January 14, 2022

A rebound from Monday's lows faded, with the key indexes all down for the week.

Via Investor's Business Daily

The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗

January 13, 2022

Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?

Via Investor's Business Daily

Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics ↗

January 10, 2022

The companies hope to cure diseases of the liver, muscle and central nervous system.

Via Investor's Business Daily

Stocks Hitting New 52-Week Lows Today ↗

January 03, 2022

On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was...

Via Benzinga

Top 5 Moonshots for 2022 Countdown: My No. 5 Pick ↗

December 22, 2021

2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.

Via InvestorPlace

NES, WTTR: The Deal That Has Penny Stock Nuverra Environmental Solutions Skyrocketing Today ↗

December 13, 2021

Nuverra Environmental (NES) stock is surging higher on Monday following news of a massive deal with Select Energy Services (WTTR).

Via InvestorPlace

BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today ↗

December 13, 2021

BELLUS Health (BLU) stock is rocketing higher on Monday and it's all thanks to data from a Phase 2b clinical trial of BLU-5937.

Via InvestorPlace

EDIT Stock: The Preclinical Data Sending Editas Medicine Rallying Today ↗

December 13, 2021

After falling 60% year to date, EDIT stock is finally reversing course and trending higher in morning trading.

Via InvestorPlace

22 Stocks Moving in Monday's Pre-Market Session ↗

December 13, 2021

Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 32.6% to $3.58 in pre-market trading after gaining more than 14% on Friday. Foghorn Therapeutics Inc. (NASDAQ: FHTX) rose...

Via Benzinga

Looking for Growth in Small and Mid Cap Life Science Stocks ↗

November 15, 2021

2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.

Via Talk Markets

Editas Medicine, Inc (EDIT) Q3 2021 Earnings Call Transcript ↗

November 08, 2021

EDIT earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Why Editas Medicine Stock Is Jumping Today ↗

November 08, 2021

The gene-editing biotech company provided its Q3 update.

Via The Motley Fool

Should You Scoop Up Shares of This Promising Biotech on the Dip? ↗

October 28, 2021

This gene-editing specialist could still be an excellent long-term play.

Via The Motley Fool

The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO ↗

October 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends Approval Of Merck, Pfizer's Pneumococcal Vaccine...

Via Benzinga

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

Editas Medicine Could Skyrocket if Its Gene Editing Therapy Proves Successful ↗

October 19, 2021

EDIT stock has been on a roller coaster this year, but it may be at an appealing price for speculative buyers who believe in its CRISPR tech.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 ↗

October 19, 2021

Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:

Via Benzinga

What's Hot in the Stock Market? ↗

October 11, 2021

We've got a look at Merck and Amazon and Warby Parker and more.

Via The Motley Fool

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 08, 2021

Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6...

Via Benzinga

3 Spooky Healthcare Stocks I Would Avoid in October ↗

October 07, 2021

Investors craving treats should look elsewhere this month.

Via The Motley Fool

Editas Stock Firestorm Rages On; CRISPR Gene-Editing Stock Flashes Sell Signal ↗

September 30, 2021

One of the leading CRISPR stock is under pressure on underwhelming data.

Via Investor's Business Daily

EDIT Stock Is Plunging 20%. Here’s the Gene-Editing News Dragging It Down. ↗

September 29, 2021

Today, investors in Editas Medicine and EDIT stock are pricing in some clinical trial results that are being viewed negatively by the market.

Via InvestorPlace

52 Biggest Movers From Yesterday ↗

September 30, 2021

Gainers Paltalk, Inc. (NASDAQ: PALT) shares jumped 60.1% to close at $8.39 on Wednesday. Smart Share Global Limited (NASDAQ: EM) jumped 36.2% to close at $3.91. Smart Share...

Via Benzinga

PreMarket Prep Stock Of The Day: Editas Medicine ↗

September 29, 2021

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 29, 2021

Gainers NuCana (NASDAQ:NCNA) stock increased by 22.36% to $2.9 during Wednesday's regular session. The current volume of 77.9 million shares is 21650.59% of NuCana...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

All News about Editas Medicine, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today